메뉴 건너뛰기




Volumn 43, Issue 6, 2015, Pages 870-883

Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; MEPHENYTOIN; PANTOPRAZOLE; VORICONAZOLE; ANTICONVULSIVE AGENT; CYP2C19 PROTEIN, HUMAN;

EID: 84940397357     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061523     Document Type: Article
Times cited : (19)

References (59)
  • 1
    • 0000501656 scopus 로고
    • Information theory and an extension of the maximum likelihood principle
    • Petrov BN and Csaki F eds, Academiai Kiado, Budapest
    • Akaike, H (1973) Information theory and an extension of the maximum likelihood principle, in Second International Symposium on Information Theory (Petrov BN and Csaki F eds) pp 267-281, Academiai Kiado, Budapest.
    • (1973) Second International Symposium on Information Theory , pp. 267-281
    • Akaike, H.1
  • 2
    • 0036020995 scopus 로고    scopus 로고
    • Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
    • Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, and Ingelman-Sundberg M (2002) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:375-383.
    • (2002) Pharmacogenetics , vol.12 , pp. 375-383
    • Aklillu, E.1    Herrlin, K.2    Gustafsson, L.L.3    Bertilsson, L.4    Ingelman-Sundberg, M.5
  • 4
    • 0013297123 scopus 로고    scopus 로고
    • Celexa., Forest Pharmaceuticals. St. Louis, MO
    • Celexa. (2009) Package insert. Forest Pharmaceuticals. St. Louis, MO.
    • (2009) Package Insert
  • 5
    • 0029587180 scopus 로고
    • Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
    • Chang M, Dahl ML, Tybring G, Götharson E, and Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363.
    • (1995) Pharmacogenetics , vol.5 , pp. 358-363
    • Chang, M.1    Dahl, M.L.2    Tybring, G.3    Götharson, E.4    Bertilsson, L.5
  • 7
    • 79960115517 scopus 로고    scopus 로고
    • Sources of interindividual variability in IVIVE of clearance: An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
    • Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, and Barter ZE (2011) Sources of interindividual variability in IVIVE of clearance: An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:623-638.
    • (2011) Xenobiotica , vol.41 , pp. 623-638
    • Cubitt, H.E.1    Yeo, K.R.2    Howgate, E.M.3    Rostami-Hodjegan, A.4    Barter, Z.E.5
  • 10
    • 80053574439 scopus 로고    scopus 로고
    • Association between CYP2C19∗17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients
    • de Vos A, van der Weide J, and Loovers HM (2011) Association between CYP2C19∗17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 11:359-367.
    • (2011) Pharmacogenomics J , vol.11 , pp. 359-367
    • De Vos, A.1    Van Der Weide, J.2    Loovers, H.M.3
  • 11
    • 34250663402 scopus 로고    scopus 로고
    • The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and warfarin as an example
    • Dickinson GL, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2007a) The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and warfarin as an example. Br J Clin Pharmacol 64:14-26.
    • (2007) Br J Clin Pharmacol , vol.64 , pp. 14-26
    • Dickinson, G.L.1    Lennard, M.S.2    Tucker, G.T.3    Rostami-Hodjegan, A.4
  • 12
    • 33846450220 scopus 로고    scopus 로고
    • Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: Dextromethorphan as a model application
    • Dickinson GL, Rezaee S, Proctor NJ, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2007b) Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol 47:175-186.
    • (2007) J Clin Pharmacol , vol.47 , pp. 175-186
    • Dickinson, G.L.1    Rezaee, S.2    Proctor, N.J.3    Lennard, M.S.4    Tucker, G.T.5    Rostami-Hodjegan, A.6
  • 13
    • 79958854645 scopus 로고    scopus 로고
    • Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach
    • Duan JZ, Jackson AJ, and Zhao P (2011) Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. J Clin Pharmacol 51:1087-1100.
    • (2011) J Clin Pharmacol , vol.51 , pp. 1087-1100
    • Duan, J.Z.1    Jackson, A.J.2    Zhao, P.3
  • 15
    • 0013297123 scopus 로고    scopus 로고
    • Eliglustat., Genzyme Corporation, Cambridge, MA
    • Eliglustat. (2014) package insert. Genzyme Corporation, Cambridge, MA.
    • (2014) Package Insert
  • 19
    • 0030904031 scopus 로고    scopus 로고
    • Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
    • Goldstein JA, Ishizaki T, Chiba K, de-Morais SM, Bell D, Krahn PM, and Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64.
    • (1997) Pharmacogenetics , vol.7 , pp. 59-64
    • Goldstein, J.A.1    Ishizaki, T.2    Chiba, K.3    De-Morais, S.M.4    Bell, D.5    Krahn, P.M.6    Evans, D.A.7
  • 20
    • 84877079740 scopus 로고    scopus 로고
    • In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates
    • Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, and Tod M (2013) In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J 15:415-426.
    • (2013) AAPS J , vol.15 , pp. 415-426
    • Goutelle, S.1    Bourguignon, L.2    Bleyzac, N.3    Berry, J.4    Clavel-Grabit, F.5    Tod, M.6
  • 23
    • 33745130722 scopus 로고    scopus 로고
    • Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
    • Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 36:473-497.
    • (2006) Xenobiotica , vol.36 , pp. 473-497
    • Howgate, E.M.1    Rowland, Y.K.2    Proctor, N.J.3    Tucker, G.T.4    Rostami-Hodjegan, A.5
  • 24
    • 0037403687 scopus 로고    scopus 로고
    • Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
    • Hyland R, Jones BC, and Smith DA (2003) Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540-547.
    • (2003) Drug Metab Dispos , vol.31 , pp. 540-547
    • Hyland, R.1    Jones, B.C.2    Smith, D.A.3
  • 25
    • 0022623877 scopus 로고
    • Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital
    • Jacqz E, Hall SD, Branch RA, and Wilkinson GR (1986) Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 39:646-653.
    • (1986) Clin Pharmacol Ther , vol.39 , pp. 646-653
    • Jacqz, E.1    Hall, S.D.2    Branch, R.A.3    Wilkinson, G.R.4
  • 26
    • 67649392513 scopus 로고    scopus 로고
    • A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates
    • Jamei M, Dickinson GL, and Rostami-Hodjegan A (2009) A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 24:53-75.
    • (2009) Drug Metab Pharmacokinet , vol.24 , pp. 53-75
    • Jamei, M.1    Dickinson, G.L.2    Rostami-Hodjegan, A.3
  • 27
    • 32044456194 scopus 로고    scopus 로고
    • Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 49-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry
    • Jansson B, Elsherbiny D, and Simonsson US (2006) Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 49-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20:463-472.
    • (2006) Rapid Commun Mass Spectrom , vol.20 , pp. 463-472
    • Jansson, B.1    Elsherbiny, D.2    Simonsson, U.S.3
  • 28
    • 0031807369 scopus 로고    scopus 로고
    • Singledose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects
    • Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, and Sidhu J (1998) Singledose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 54:237-242.
    • (1998) Eur J Clin Pharmacol , vol.54 , pp. 237-242
    • Joffe, P.1    Larsen, F.S.2    Pedersen, V.3    Ring-Larsen, H.4    Aaes-Jørgensen, T.5    Sidhu, J.6
  • 29
    • 67649407499 scopus 로고    scopus 로고
    • Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: Using in vitro data as an aid to assess study power
    • Johnson TN, Kerbusch T, Jones B, Tucker GT, Rostami-Hodjegan A, and Milligan PA (2009) Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm Stat 8:186-202.
    • (2009) Pharm Stat , vol.8 , pp. 186-202
    • Johnson, T.N.1    Kerbusch, T.2    Jones, B.3    Tucker, G.T.4    Rostami-Hodjegan, A.5    Milligan, P.A.6
  • 30
    • 0031845066 scopus 로고    scopus 로고
    • Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6
    • Ko JW, Desta Z, and Flockhart DA (1998) Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26:775-778.
    • (1998) Drug Metab Dispos , vol.26 , pp. 775-778
    • Ko, J.W.1    Desta, Z.2    Flockhart, D.A.3
  • 31
    • 84896092716 scopus 로고    scopus 로고
    • MicroRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450
    • Lamba V, Ghodke Y, Guan W, and Tracy TS (2014) microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. Biochem Biophys Res Commun 445:404-411.
    • (2014) Biochem Biophys Res Commun , vol.445 , pp. 404-411
    • Lamba, V.1    Ghodke, Y.2    Guan, W.3    Tracy, T.S.4
  • 32
  • 33
    • 45749083522 scopus 로고    scopus 로고
    • Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- And third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations
    • Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, and Lin CY, et al. (2008) Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- And third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 84:347-361.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 347-361
    • Myrand, S.P.1    Sekiguchi, K.2    Man, M.Z.3    Lin, X.4    Tzeng, R.Y.5    Teng, C.H.6    Hee, B.7    Garrett, M.8    Kikkawa, H.9    Lin, C.Y.10
  • 34
    • 0020425640 scopus 로고
    • Kinetics of citalopram in man; plasma levels in patients
    • Overø FK (1982) Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 6:311-318.
    • (1982) Prog Neuropsychopharmacol Biol Psychiatry , vol.6 , pp. 311-318
    • Overoø, F.K.1
  • 35
    • 4444278991 scopus 로고    scopus 로고
    • The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes
    • Parkinson A, Mudra DR, Johnson C, Dwyer A, and Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209.
    • (2004) Toxicol Appl Pharmacol , vol.199 , pp. 193-209
    • Parkinson, A.1    Mudra, D.R.2    Johnson, C.3    Dwyer, A.4    Carroll, K.M.5
  • 37
    • 0013297123 scopus 로고    scopus 로고
    • Protonix., Wyeth Pharmaceuticals, Philadelphia, PA
    • Protonix. (2000) Package insert. Wyeth Pharmaceuticals, Philadelphia, PA.
    • (2000) Package Insert
  • 38
    • 42449124602 scopus 로고    scopus 로고
    • The "albumin effect" and in vitro-in vivo extrapolation: Sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9
    • Rowland A, Elliot DJ, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870-877.
    • (2008) Drug Metab Dispos , vol.36 , pp. 870-877
    • Rowland, A.1    Elliot, D.J.2    Knights, K.M.3    Mackenzie, P.I.4    Miners, J.O.5
  • 39
    • 38349110295 scopus 로고    scopus 로고
    • Impact of the ultrarapid CYP2C19∗17 allele on serum concentration of escitalopram in psychiatric patients
    • Rudberg I, Mohebi B, Hermann M, Refsum H, and Molden E (2008) Impact of the ultrarapid CYP2C19∗17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322-327.
    • (2008) Clin Pharmacol Ther , vol.83 , pp. 322-327
    • Rudberg, I.1    Mohebi, B.2    Hermann, M.3    Refsum, H.4    Molden, E.5
  • 40
    • 0024336503 scopus 로고
    • S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin
    • Sanz EJ, Villén T, Alm C, and Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45:495-499.
    • (1989) Clin Pharmacol Ther , vol.45 , pp. 495-499
    • Sanz, E.J.1    Villén, T.2    Alm, C.3    Bertilsson, L.4
  • 41
    • 79960613122 scopus 로고    scopus 로고
    • Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy
    • Clinical Pharmacogenetics Implementation Consortium
    • Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, and Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90:328-332.
    • (2011) Clin Pharmacol Ther , vol.90 , pp. 328-332
    • Scott, S.A.1    Sangkuhl, K.2    Gardner, E.E.3    Stein, C.M.4    Hulot, J.S.5    Johnson, J.A.6    Roden, D.M.7    Klein, T.E.8    Shuldiner, A.R.9
  • 42
    • 30344457586 scopus 로고    scopus 로고
    • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    • Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, and Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 103-113
    • Sim, S.C.1    Risinger, C.2    Dahl, M.L.3    Aklillu, E.4    Christensen, M.5    Bertilsson, L.6    Ingelman-Sundberg, M.7
  • 44
    • 2042431033 scopus 로고    scopus 로고
    • Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population
    • Sviri S, Shpizen S, Leitersdorf E, Levy M, and Caraco Y (1999) Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther 65:275-282.
    • (1999) Clin Pharmacol Ther , vol.65 , pp. 275-282
    • Sviri, S.1    Shpizen, S.2    Leitersdorf, E.3    Levy, M.4    Caraco, Y.5
  • 45
    • 0026934962 scopus 로고
    • A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio
    • Tybring G and Bertilsson L (1992) A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 2:241-243.
    • (1992) Pharmacogenetics , vol.2 , pp. 241-243
    • Tybring, G.1    Bertilsson, L.2
  • 46
    • 0016174577 scopus 로고
    • Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes
    • Van-der-Hoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
    • (1974) J Biol Chem , vol.249 , pp. 6302-6310
    • Van-Der-Hoeven, T.A.1    Coon, M.J.2
  • 48
    • 79955036726 scopus 로고    scopus 로고
    • Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 49-hydroxylation and omeprazole 59-hydroxylation
    • Wang H, An N, Wang H, Gao Y, Liu D, Bian T, Zhu J, and Chen C (2011b) Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 49-hydroxylation and omeprazole 59-hydroxylation. Drug Metab Dispos 39:830-837.
    • (2011) Drug Metab Dispos , vol.39 , pp. 830-837
    • Wang, H.1    An, N.2    Wang, H.3    Gao, Y.4    Liu, D.5    Bian, T.6    Zhu, J.7    Chen, C.8
  • 50
    • 0021684926 scopus 로고
    • Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
    • Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, and Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773-780.
    • (1984) Clin Pharmacol Ther , vol.36 , pp. 773-780
    • Wedlund, P.J.1    Aslanian, W.S.2    McAllister, C.B.3    Wilkinson, G.R.4    Branch, R.A.5
  • 52
    • 32944471001 scopus 로고    scopus 로고
    • So many studies, too few subjects: Establishing functional relevance of genetic polymorphisms on pharmacokinetics
    • Williams JA, Johnson K, Paulauskis J, and Cook J (2006) So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 46:258-264.
    • (2006) J Clin Pharmacol , vol.46 , pp. 258-264
    • Williams, J.A.1    Johnson, K.2    Paulauskis, J.3    Cook, J.4
  • 53
    • 84894526589 scopus 로고    scopus 로고
    • Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: Application to predict drug/genetic interactions
    • Wu F, Gaohua L, Zhao P, Jamei M, Huang SM, Bashaw ED, and Lee SC (2014) Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: Application to predict drug/genetic interactions. Pharm Res 31:1919-1929.
    • (2014) Pharm Res , vol.31 , pp. 1919-1929
    • Wu, F.1    Gaohua, L.2    Zhao, P.3    Jamei, M.4    Huang, S.M.5    Bashaw, E.D.6    Lee, S.C.7
  • 54
    • 8244249473 scopus 로고    scopus 로고
    • Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
    • Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, and Xu ZH, et al. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281:604-609.
    • (1997) J Pharmacol Exp Ther , vol.281 , pp. 604-609
    • Xiao, Z.S.1    Goldstein, J.A.2    Xie, H.G.3    Blaisdell, J.4    Wang, W.5    Jiang, C.H.6    Yan, F.X.7    He, N.8    Huang, S.L.9    Xu, Z.H.10
  • 55
    • 84888613878 scopus 로고    scopus 로고
    • CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling
    • Xu C, Quinney SK, Guo Y, Hall SD, Li L, and Desta Z (2013) CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos 41:2004-2011.
    • (2013) Drug Metab Dispos , vol.41 , pp. 2004-2011
    • Xu, C.1    Quinney, S.K.2    Guo, Y.3    Hall, S.D.4    Li, L.5    Desta, Z.6
  • 56
    • 84878015548 scopus 로고    scopus 로고
    • Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure
    • Yeo KR, Kenny JR, and Rostami-Hodjegan A (2013) Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. Eur J Clin Pharmacol 69:1311-1320.
    • (2013) Eur J Clin Pharmacol , vol.69 , pp. 1311-1320
    • Yeo, K.R.1    Kenny, J.R.2    Rostami-Hodjegan, A.3
  • 59


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.